Zacks Investment Research upgraded shares of Histogenics Corp (NASDAQ:HSGX) from a hold rating to a buy rating in a research report report published on Tuesday. They currently have $2.00 price target on the biotechnology company’s stock.

According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “

A number of other equities research analysts have also issued reports on the company. HC Wainwright set a $4.00 target price on Histogenics Corp and gave the company a buy rating in a research note on Saturday, May 13th. Canaccord Genuity reiterated a buy rating on shares of Histogenics Corp in a research note on Thursday, May 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Histogenics Corp has an average rating of Buy and an average price target of $5.10.

Histogenics Corp (NASDAQ:HSGX) traded down 2.35% during trading on Tuesday, reaching $1.66. The company’s stock had a trading volume of 20,620 shares. The company’s market capitalization is $34.27 million. Histogenics Corp has a 1-year low of $1.45 and a 1-year high of $4.47. The company’s 50-day moving average is $1.71 and its 200-day moving average is $1.80.

Histogenics Corp (NASDAQ:HSGX) last posted its earnings results on Thursday, May 11th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.07. During the same period last year, the business posted ($0.60) earnings per share. Equities analysts anticipate that Histogenics Corp will post ($1.33) EPS for the current year.

WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/05/19/histogenics-corp-hsgx-lifted-to-buy-at-zacks-investment-research.html.

Large investors have recently modified their holdings of the stock. Third Security LLC acquired a new stake in shares of Histogenics Corp during the fourth quarter worth $4,493,000. Perceptive Advisors LLC acquired a new stake in shares of Histogenics Corp during the fourth quarter worth $2,968,000. Armistice Capital LLC raised its stake in shares of Histogenics Corp by 376.3% in the fourth quarter. Armistice Capital LLC now owns 1,264,000 shares of the biotechnology company’s stock worth $2,111,000 after buying an additional 998,645 shares during the period. Sabby Management LLC raised its stake in shares of Histogenics Corp by 15.9% in the first quarter. Sabby Management LLC now owns 1,095,422 shares of the biotechnology company’s stock worth $1,895,000 after buying an additional 150,531 shares during the period. Finally, Vanguard Group Inc. acquired a new stake in shares of Histogenics Corp during the first quarter worth $481,000. Hedge funds and other institutional investors own 45.98% of the company’s stock.

About Histogenics Corp

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

5 Day Chart for NASDAQ:HSGX

Get a free copy of the Zacks research report on Histogenics Corp (HSGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Histogenics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp and related stocks with our FREE daily email newsletter.